Viamet develops traditional small molecule compounds that potently and selectively inhibit clinically-important metalloenzymes. Our therapeutic programs target validated metalloenzymes in the fields of infectious disease and oncology where current inhibitors suffer greatly from a variety of clinical efficacy and safety problems. By applying our Metallophile^® Technology to known inhibitors we have rapidly generated clinical candidates and exciting second-generation compounds.

VT-1161

A small molecule inhibitor of lanosterol demethylase (CYP51), an enzyme involved in the synthesis of fungal cell wall sterols. VT-1161 is a highly potent and selective CYP51 inhibitor with broad activity against a wide spectrum of yeasts and dermatophytes. The molecule has shown robust activity in multiple preclinical animal models with excellent oral pharmacokinetic and safety profiles. VT-1161 is in Phase 1 clinical testing for the oral treatment of onychomycosis and candidiasis.

VT-1129

A small molecule inhibitor of lanosterol demethylase (CYP51), an enzyme involved in the synthesis of fungal cell wall sterols. VT-1129 is a highly potent and selective CYP51 inhibitor with broad activity against a wide spectrum of yeasts, including Cryptococcus neoformans and Cryptococcus gattii. The molecule has shown robust activity in preclinical animal models of cryptococcal meningitis with high CNS penetration and excellent oral pharmacokinetic and safety profiles. VT-1129 is in late-stage preclinical testing for the oral treatment of cryptococcal meningitis. VT-1129 is being developed through the financial support of the National Institutes of Health Therapeutics for Rare and Neglected Diseases (TRND) program.

VT-1598

A small molecule inhibitor of lanosterol demethylase (CYP51), an enzyme involved in the synthesis of fungal cell wall sterols. VT-1598 is a highly potent and selective CYP51 inhibitor with broad activity against a wide spectrum of yeasts, molds and dermatophytes. The molecule has shown robust activity in preclinical animal models and excellent oral pharmacokinetic and safety profiles. VT-1598 is a candidate-ready molecule for the safe and effective treatment of invasive mold and yeast infections.

VT-464

A small molecule inhibitor of 17-alpha hydroxylase/17-20 lyase (CYP17), the rate-limiting enzyme in the synthesis of androgens and estrogens. CYP17 is a metalloenzyme that has both "hydroxylase" and "lyase" functions. VT-464 is a highly potent and lyase selective CYP17 inhibitor. In preclinical animal models, VT-464 has demonstrated robust anti-tumor activity, excellent oral pharmacokinetic and safety profiles and lyase-selective CYP17 inhibition with minimal impact on mineralocorticoids, glucocorticoids and upstream steroids such as progesterone and pregnenolone. VT-464 is in Phase 1/2 clinical testing for the oral treatment of castration-resistant prostate cancer without the need for co-administration with corticosteroids such as prednisone.